142 related articles for article (PubMed ID: 21944982)
1. Waldenstrom's macroglobulinemia presenting as a perinephric mass.
Therasse CJ; Casalino DD
J Urol; 2011 Nov; 186(5):2067-8. PubMed ID: 21944982
[No Abstract] [Full Text] [Related]
2. The Case ∣ Hyperbicarbonatemia in a patient with Waldenstrom's macroglobulinemia. Pseudohyperbicarbonatemia due to paraproteinemia.
Krish P; Jhaveri KD
Kidney Int; 2012 Mar; 81(6):603-5. PubMed ID: 22373713
[No Abstract] [Full Text] [Related]
3. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
Liberato B; Riethmuller A; Comenzo RL; Lis E; Raizer JJ
J Neurooncol; 2003 Jun; 63(2):207-11. PubMed ID: 12825826
[TBL] [Abstract][Full Text] [Related]
4. Improvement of the thermal amplitude after rituximab treatment for cold agglutinin disease with Waldenström's macroglobulinemia.
Hattori N; Ishii N; Ariizumi H; Adachi D; Matsuda I; Nakamaki T; Tomoyasu S
Ann Hematol; 2010 Jan; 89(1):103-4. PubMed ID: 19513714
[No Abstract] [Full Text] [Related]
5. Waldenstrom's macroglobulinaemia: to treat or not to treat?
Sundriyal D; Kumar N; Kotwal S; Shirsi N
BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25414220
[TBL] [Abstract][Full Text] [Related]
6. Prognosis and treatment of Waldenström's macroglobulinemia.
Louw VJ; Webb MJ
Transfus Apher Sci; 2010 Apr; 42(2):193-7. PubMed ID: 20117052
[TBL] [Abstract][Full Text] [Related]
7. Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
Anderson KC; Alsina M; Bensinger W; Biermann JS; Cohen AD; Devine S; Djulbegovic B; Faber EA; Gasparetto C; Hernandez-Ilizaliturri F; Huff CA; Kassim A; Krishnan AY; Medeiros BC; Meredith R; Raje N; Schriber J; Singhal S; Somlo G; Stockerl-Goldstein K; Treon SP; Tricot G; Weber DM; Yahalom J; Yunus F; Kumar R; Shead DA;
J Natl Compr Canc Netw; 2012 Oct; 10(10):1211-9. PubMed ID: 23054875
[TBL] [Abstract][Full Text] [Related]
8. Novel agents in the treatment of Waldenström's macroglobulinemia.
Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
[TBL] [Abstract][Full Text] [Related]
9. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
[TBL] [Abstract][Full Text] [Related]
10. Waldenström's macroglobulinaemia: laboratory diagnosis and treatment.
Owen RG; Johnson SA; Morgan GJ
Hematol Oncol; 2000 Jun; 18(2):41-9. PubMed ID: 10960874
[No Abstract] [Full Text] [Related]
11. Marked increase in serum IgM during treatment of Waldenstrom's macroglobulinemia with cladribine.
Krishna VM; Carey RW; Bloch KJ
N Engl J Med; 2003 May; 348(20):2045-6. PubMed ID: 12748329
[No Abstract] [Full Text] [Related]
12. Flare in neuropathy following rituximab therapy for Waldenstrom's macroglobulinemia.
Noronha V; Fynan TM; Duffy T
J Clin Oncol; 2006 Jan; 24(1):e3. PubMed ID: 16382111
[No Abstract] [Full Text] [Related]
13. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
[TBL] [Abstract][Full Text] [Related]
14. [Pathology, diagnostics, and treatment of Waldenström's macroglobulinaemia].
Holmström MO
Ugeskr Laeger; 2011 Oct; 173(41):2557-60. PubMed ID: 21985832
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
[TBL] [Abstract][Full Text] [Related]
16. Waldenström's macroglobulinemia.
Gertz MA; Fonseca R; Rajkumar SV
Oncologist; 2000; 5(1):63-7. PubMed ID: 10706651
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine therapy in a patient with progressive symptomatic Waldenström's macroglobulinemia.
Hałaburda K; Hellmann A
Acta Haematol Pol; 1994; 25(1):63-7. PubMed ID: 8209618
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Waldenström's macroglobulinemia with rituximab.
Dimopoulos MA; Zervas C; Zomas A; Kiamouris C; Viniou NA; Grigoraki V; Karkantaris C; Mitsouli C; Gika D; Christakis J; Anagnostopoulos N
J Clin Oncol; 2002 May; 20(9):2327-33. PubMed ID: 11981004
[TBL] [Abstract][Full Text] [Related]
19. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.
Byrd JC; White CA; Link B; Lucas MS; Velasquez WS; Rosenberg J; Grillo-López AJ
Ann Oncol; 1999 Dec; 10(12):1525-7. PubMed ID: 10643548
[TBL] [Abstract][Full Text] [Related]
20. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.
Dimopoulos MA; Zervas C; Zomas A; Hamilos G; Gika D; Efstathiou E; Panayiotidis P; Vervessou E; Anagnostopoulos N; Christakis J
Clin Lymphoma; 2002 Dec; 3(3):163-6. PubMed ID: 12521393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]